Yale University isn't to receive 240m shares in VHL, Tylemahos.
Rather the shares - equal to 30pc of expanded VHL capital - will be owned by shareholders in Pathway Oncology Pty Ltd, a Brisbane-based shell controlled by venture capitalist and VHL director-elect, Paul Hopper.
As I understand it, VHL will acquire Pathway and Pathway, as a Virax subsidiary, will be liable to pay Yale monies - yet to be disclosed - under the licensing deal apparently negotiated by Hopper.
These deals will need to be placed before shareholders.
Some will apply careful scrutiny before ratifying.
VHL Price at posting:
1.5¢ Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)